Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Monday,Benzinga reports. The firm currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

Several other research analysts have also weighed in on GANX. Oppenheimer restated an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, August 9th.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.74 on Monday. The firm’s fifty day simple moving average is $2.08 and its 200-day simple moving average is $1.71. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The stock has a market cap of $46.14 million, a PE ratio of -1.58 and a beta of 0.33. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $5.33.

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds have recently added to or reduced their stakes in GANX. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics in the second quarter valued at about $66,000. Renaissance Technologies LLC raised its position in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the last quarter. Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter valued at approximately $422,000. Finally, Geode Capital Management LLC grew its holdings in Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.